David A. Siegel Atossa Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 54,200 shares of ATOS stock, worth $81,300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
54,200
Previous 18,500
192.97%
Holding current value
$81,300
Previous $33,000
93.94%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding ATOS
# of Institutions
88Shares Held
25.9MCall Options Held
404KPut Options Held
83.6K-
Black Rock Inc. New York, NY9.2MShares$13.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.6MShares$9.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.81MShares$4.22 Million0.0% of portfolio
-
State Street Corp Boston, MA1.66MShares$2.49 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.31MShares$1.97 Million0.0% of portfolio
About ATOSSA THERAPEUTICS, INC.
- Ticker ATOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,624,000
- Market Cap $190M
- Description
- Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...